However , rates of major and non-major clinically relevant bleeding with rivaroxaban vs. warfarin were higher in patients with SVD ( @ % rivaroxaban vs. @ % warfarin ; HR @ , @ % CI @-@ @ ) vs. those without ( @ % rivaroxaban vs. @ % warfarin ; HR @ , @ % CI @-@ @ ; interaction P = @ ) , even when controlling for risk factors and potential confounders .